-
The Journal of Rheumatology Oct 1991
Topics: Humans; Penicillamine; Scleroderma, Systemic
PubMed: 1765965
DOI: No ID Found -
Annals of the Rheumatic Diseases Feb 1977A case of dermatomyositis developing during the course of treatment with D-penicillamine in a patient with rheumatoid arthritis is described. Complete remission occurred...
A case of dermatomyositis developing during the course of treatment with D-penicillamine in a patient with rheumatoid arthritis is described. Complete remission occurred on withdrawal of the drug. Possible alternative diagnoses are discussed.
Topics: Arthritis, Rheumatoid; Dermatomyositis; Female; Humans; Middle Aged; Penicillamine
PubMed: 843119
DOI: 10.1136/ard.36.1.94 -
Biochemical Pharmacology Oct 1985We previously observed that postmitochondrial supernatant (S9) from rat liver and kidney homogenates transforms L-cysteine into a mutagen that reverts bacteria of the...
We previously observed that postmitochondrial supernatant (S9) from rat liver and kidney homogenates transforms L-cysteine into a mutagen that reverts bacteria of the strain Salmonella typhimurium TA100 to histidine independence. In the present study the enantiomers of cysteine and penicillamine (beta, beta-dimethylcysteine) have been investigated for mutagenicity. The Salmonella typhimurium strain TA92 was found to be more sensitive than TA100 to the mutagenic action of L-cysteine and was therefore also included. This strain allowed the unambiguous realization of a (weak) mutagenic effect of L-cysteine even in the absence of mammalian enzyme preparations. D-cysteine did not show mutagenicity under any experimental conditions. However, it was strongly bacteriotoxic. On the other hand, both enantiomers of penicillamine exerted clear mutagenic effects. Qualitatively, their mutagenicity was similar to that of L-cysteine in the following respects: the penicillamines were directly mutagenic, their mutagenicity was enhanced by S9, kidney S9 enhanced the mutagenicity more than did liver S9, TA92 was more sensitive than TA100. Thereby it is noteworthy that the ratios of the specific mutagenicities in the two strains were virtually identical in the direct, kidney-S9-mediated and liver-S9-mediated tests suggesting that the ultimate mutagens under these different metabolic conditions were identical. On the other hand, substantial quantitative differences in the mutagenicity between the beta-thiol amino acids were observed. L-penicillamine was about eight times more mutagenic than the clinically used enantiomer, D-penicillamine. In the direct tests, the mutagenic potency of L-cysteine was equal to that of D-penicillamine. In the S9-mediated experiments, the mutagenic potency of L-cysteine was intermediate between those of L- and D-penicillamine.
Topics: Animals; Cysteine; Kidney; Liver; Male; Mutagenicity Tests; Mutagens; Penicillamine; Rats; Rats, Inbred Strains; Salmonella typhimurium; Stereoisomerism
PubMed: 3902028
DOI: 10.1016/0006-2952(85)90237-0 -
Scandinavian Journal of Rheumatology 1987The bioavailability of D-penicillamine was measured in 24 patients with generalized scleroderma (Progressive Systemic Sclerosis, PSS). Esophageal changes characteristic...
The bioavailability of D-penicillamine was measured in 24 patients with generalized scleroderma (Progressive Systemic Sclerosis, PSS). Esophageal changes characteristic of generalized scleroderma were present in 15 of the patients, and 3 of those patients had duodenal involvements as well. The plasma concentrations of D-penicillamine were measured at 0 h, 1 h, 2 h, and 4 h after an oral dose of 300 mg D-penicillamine. Patients with duodenal and/or esophageal changes specific for scleroderma had significantly lower bioavailability of D-penicillamine than scleroderma patients without gastrointestinal manifestations. The decreased plasma D-penicillamine in scleroderma patients with involvement of the gastrointestinal tract may be due to an increased degradation of D-penicillamine in the gastrointestinal tract and/or an impaired absorption of the drug. Since the plasma level of D-penicillamine is so sensitive to pathological changes of the gastrointestinal tract, it may be advisable to adjust the dose of D-penicillamine on the basis of measurements of the plasma concentration of D-penicillamine.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Capsules; Esophageal Diseases; Female; Gastrointestinal Diseases; Humans; Intestinal Absorption; Male; Middle Aged; Penicillamine; Scleroderma, Systemic
PubMed: 3602943
DOI: 10.3109/03009748709102917 -
Bailliere's Clinical Rheumatology Aug 1989
Review
Topics: Chemical Phenomena; Chemistry; Gastrointestinal Diseases; Gold; Humans; Penicillamine
PubMed: 2670263
DOI: 10.1016/s0950-3579(89)80029-9 -
Arzneimittel-Forschung Feb 1975In acute pharmacological experiments, D-betta,betta-dimethylcysteine (D-penicillamine, Metalcaptase) stands out for its good oral and intravenous tolerance. In case of...
In acute pharmacological experiments, D-betta,betta-dimethylcysteine (D-penicillamine, Metalcaptase) stands out for its good oral and intravenous tolerance. In case of high dosage, slight analgesic and anti-inflammatory effects can be found. The influence on newly formed connective tissue is not uniform. While the wet and dry weights of granulomata are not influenced, D-penicillamine causes a retardation of the healing process in standardised burns. Mechanical properties of connective tissue such as the resistance of cut wounds, the tearing strength of excised dorsal skin strips or of the capsule of the knee-joint show after long-term treatment with D-penicillamine a dose-dependent change in the sense of a decrease of the data obtained. After discontinuation of the test substance, the data reach standard values within a few days.
Topics: Administration, Oral; Animals; Biomechanical Phenomena; Burns; Edema; Elasticity; Female; Granulation Tissue; Granuloma; Injections, Intravenous; Knee Joint; Lethal Dose 50; Male; Mice; Penicillamine; Rats; Skin; Time Factors; Wound Healing
PubMed: 1173030
DOI: No ID Found -
Antibiotiki Sep 1969
Topics: Animals; Blood Cell Count; Blood Cells; Chemistry Techniques, Analytical; Dogs; Gastrointestinal Motility; Guinea Pigs; Injections, Intravenous; Kidney; Kidney Function Tests; Lead; Lead Poisoning; Liver; Liver Function Tests; Mice; Penicillamine; Rabbits
PubMed: 5361828
DOI: No ID Found -
The Journal of Rheumatology 1979
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Penicillamine
PubMed: 439108
DOI: No ID Found -
Agents and Actions. Supplements 1979Perhaps the most important conclusion is that much remains to be learnt about how to use penicillamine in clinical practice. The results described have been obtained by... (Clinical Trial)
Clinical Trial
Perhaps the most important conclusion is that much remains to be learnt about how to use penicillamine in clinical practice. The results described have been obtained by observing groups of patients on various fixed schedules of dosage. There may be a case for using a more flexible system but this makes comparisons difficult and at this stage predetermined fixed schedules have been preferred. A total daily dose of 1500 mg is clearly excessive and probably unnecessary. There is some suggestion that administration between meals produces better and perhaps more predictable absorption. If used in this way the total daily dose should be lower than the one found most suitable when the drug is given with food. Experience to date favours a daily total of 375 mg given between meals. The late onset of some adverse reactions in patients on low doses suggest that the total cumulative dose may be relevant and that some toxic reactions are liable to occur when a certain total intake has been reached. No mention has been made in this survey of comparisons with other drugs. The main task has been seen to be the exploration of various dosage schedules in the hope of finding an effective dose which does not produce a high incidence of adverse effect. Only when this information has been obtained will it once again become relevant to test the drug under control conditions either against an inactive placebo or some other anti-rheumatoid drug.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Administration Schedule; Humans; Penicillamine
PubMed: 393102
DOI: No ID Found -
JAMA Apr 1980
Topics: Bronchitis; Connective Tissue Diseases; Humans; Penicillamine
PubMed: 7359732
DOI: No ID Found